Related Experiment Video
Updated: May 15, 2026
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Mpox vaccine acceptance and uptake in Africa: a systematic review and meta-analysis
Fabrice Zobel Lekeumo Cheuyem1,2, Andreas Ateke Njoh3, Chabeja Achangwa4
1Department of Public Health, Faculty of Medicine and Biomedical Sciences, The University of Yaoundé 1, Yaoundé, Cameroon. zobelcheuyem@gmail.com.
Background:
Mpox remains a significant public health threat in Africa, with recent outbreaks driven by newly emergent clades I and II. Vaccination is a critical intervention for outbreak control, yet detailed evidence on vaccine acceptance and uptake across the continent has not been comprehensively synthesized. This study aimed to determine the pooled prevalence and determinants of mpox vaccine acceptance and uptake in Africa during and after the global mpox outbreak.
Methods:
We searched PubMed, Scopus, Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), ScienceDirect, and African Journals Online. Studies conducted between 2022 and 2024 were included. Articles available in French and English were considered. A random-effects model was used to pool the estimates. Subgroup analyses explored heterogeneity. Key determinants of vaccine acceptance and uptake were systematically identified from the included report findings.
Results:
The pooled mpox vaccine acceptance rate in Africa was 54.97% (95% confidence interval (CI): 49.22-60.59; 15,613 participants; 22 records, 10 countries) with high heterogeneity (I² = 97.8%; p < 0.001). The pooled willingness to vaccinate differ significantly by participant type (p < 0.001). It was higher among the general population (62.02%; 95% CI: 52.86-70.39; n = 9 records; I² = 98.8%) than among healthcare workers (47.97%; 95% CI: 37.35-58.78; n = 6 records; I² = 97.1%). In contrast, pooled vaccine uptake was low at 3.40% (95% CI: 0.56-17.96; 5,740 participants; 8 records, 10 countries), indicating high heterogeneity (I² = 99.7%; p < 0.001). A significant difference (p < 0.001) was observed between studies conducted in the Central Africa region (2.24%: 95% CI: 0.46-10.14; n = 4 records; I² = 81.6%) and the Western zone (38.13%; 95% CI: 27.21-50.39; n = 2 records; I² = 97.5%). Key factors positively influencing acceptance included higher education, greater mpox knowledge, higher risk perception, and trust in health authorities and vaccine safety.
Conclusions:
There is a substantial gap between mpox vaccine acceptance and actual uptake in Africa. Strategies to enhance vaccination must address both demand and supply challenges as well as equitable distribution. These findings underscore the need for context-specific, multi-level interventions to translate reported willingness into actual vaccine uptake.
Systematic Review Registration:
PROSPERO CRD420251126033.
Insights
Mpox vaccine acceptance in Africa is over 50%, but uptake remains low at 3.4%. Interventions must address demand, supply, and equitable distribution to improve mpox vaccination rates.
Area of Science:
- Public Health
- Epidemiology
- Vaccinology
Background:
- Mpox (formerly monkeypox) poses a significant public health threat in Africa, with recent outbreaks driven by emergent clades.
- Vaccination is crucial for controlling mpox outbreaks, yet comprehensive data on vaccine acceptance and uptake across Africa is limited.
- This study synthesizes evidence on mpox vaccine acceptance and uptake in Africa during and after the global mpox outbreak.
Purpose of the Study:
- To determine the pooled prevalence of mpox vaccine acceptance and uptake in Africa.
- To identify key determinants influencing mpox vaccine acceptance and uptake across the continent.
- To provide evidence for targeted interventions to improve mpox vaccination coverage in Africa.
Main Methods:
- Systematic literature search of multiple databases (PubMed, Scopus, CINAHL, etc.) for studies published between 2022 and 2024.
- Inclusion of articles in English and French, using a random-effects model to pool prevalence estimates.
- Subgroup analyses to explore heterogeneity and systematic identification of key determinants of vaccine acceptance and uptake.
Main Results:
- Pooled mpox vaccine acceptance was 54.97% across 10 African countries, with significant heterogeneity.
- Vaccine acceptance was higher in the general population (62.02%) compared to healthcare workers (47.97%).
- Pooled vaccine uptake was low at 3.40%, with significant regional differences observed (Central Africa: 2.24%; Western zone: 38.13%).
- Positive determinants for acceptance included higher education, mpox knowledge, risk perception, and trust in vaccine safety and health authorities.
Conclusions:
- A substantial gap exists between mpox vaccine acceptance and actual uptake in Africa.
- Strategies to enhance mpox vaccination must address both demand- and supply-side challenges, alongside equitable distribution.
- Context-specific, multi-level interventions are necessary to translate willingness into actual mpox vaccine uptake.
More Related Videos
Related Concept Videos
01:51Vaccinations
01:21Vaccines